Abiopharma

🔍 Noble Ryan S. (Executive)

Company: KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU)

Report Date: 2026-06-30

Detailed Transactions and Holdings:

• Acquired 7,206 shares of Common Stock (Direct)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 21,049.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,000 shares of Common Stock at $36.25 per share (Direct)
  Date: 2026-06-30 | Code: D | equity_swap_involved: 0 | shares_owned_after: 18,049.00 | transaction_form_type: 4
• Sold 1,809 shares of Common Stock at $36.25 per share (Direct)
  Date: 2026-06-30 | Code: F | equity_swap_involved: 0 | shares_owned_after: 16,240.00 | transaction_form_type: 4
• Sold 5,942 shares of Restricted Stock Units FY24 (Derivative)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 534 shares of Restricted Stock Units FY25 (Derivative)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,939.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4
• Sold 730 shares of Restricted Stock Units FY26 (Derivative)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,650.00 | transaction_form_type: 4 | Footnotes: F1, F1, F5, F5

Footnotes:

• F1: Service-based restricted stock units ("RSUs") convert to common stock on a one-for-one basis.
• F2: On June 30, 2026, 3,617 of the reporting person's performance-based RSUs were settled following certification of performance results for the applicable performance period, which resulted in the performance-based RSUs vesting at 150% of target. In the settlement, the reporting person received (a) 2,426 shares and (b) pursuant to an election made by the reporting person, cash in settlement of RSUs otherwise entitling the reporting person to receive 3,000 shares. In addition, on June 30, 2026, 516 of the reporting person's service-based RSUs vested. Accordingly, the reporting person received 2,942 shares in the aggregate as a result of the settlement of these RSUs, as well as a payment in cash in lieu of 3,000 shares.
• F3: On June 28, 2023, the reporting person was granted RSUs that vest as follows: (a) 30% of the number of RSUs subject to the award consisted of service-based RSUs that vested in three equal annual installments beginning on June 30, 2024, subject to the reporting person's continued employment with the Company, and (b) 70% of the number of RSUs subject to the award consisted of performance based RSUs that vested only if performance goals were achieved over a three-year period. The actual number of shares (if any) received upon settlement of the performance-based RSUs depended on continued employment and actual performance over the three-year period.
• F4: On June 28, 2024, the reporting person was granted RSUs that vest as follows: (a) 40% of the number of RSUs subject to the award consisted of service-based RSUs that vest in three equal annual installments beginning on June 30, 2025, subject to the reporting person's continued employment with the Company, and (b) 60% of the number of RSUs subject to the award consisted of performance based RSUs that vest only if performance goals were achieved over a three-year period. The actual number of shares (if any) received upon settlement of the performance-based RSUs depends on continued employment and actual performance over the three-year period.
• F5: On June 25, 2025, the reporting person was granted RSUs that vest as follows: (a) 50% of the number of RSUs subject to the award consisted of service-based RSUs that vested in three equal annual installments beginning on June 30, 2026, subject to the reporting person's continued employment with the Company, and (b) 50% of the number of RSUs subject to the award consisted of performance based RSUs that vested only if performance goals were achieved over a three-year period. The actual number of shares (if any) received upon settlement of the performance-based RSUs depends on continued employment and actual performance over the three-year period.